News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
Solidion patents extreme-climate battery for orbit AI data centers
Solidion Technology claims a patented battery design for low Earth orbit operations and lunar infrastructure. The company targets space-based AI compute, but independent performance data is not yet public.
JJP Biologics Halts Dapsone Use in IgA Disease With Anti-CD89 Drug
Nebaprubart showed clinical activity within one week in a phase 1b trial, letting patients stop immunosuppressive therapy. The company plans RA and IgA nephropathy trials in 2026.
CSL Gets EU Approval for Measles Protection Without Vaccination
European Commission authorises Privigen for measles prophylaxis in patients who cannot be vaccinated. The move addresses a sharp rise in European measles cases in 2024–2025.
J&J's SLE Drug Hits Phase 2 Target, Holds Gains to Week 52
Nipocalimab met its primary endpoint at 24 weeks in moderate-to-severe lupus, with sustained disease reduction through week 52. The FcRn blocker showed stronger response in autoantibody-positive patients, who make up roughly 80% of SLE cases.
Lilly's $7B Kelonia bet pays off: in vivo CAR-T hits 100% response in myeloma
Kelonia's KLN-1010 achieved complete or near-complete remission in all evaluable myeloma patients at ASCO 2026, with CAR-T persistence exceeding typical ex vivo therapies. Two other in vivo cell programs also advanced.
US Lawmakers Target $136B in Chinese Biotech Deals with New Bill
Michigan lawmakers propose BINSA to let Congress review and block American pharma investments in China. The move follows $25.7B in recent mega-deals by Pfizer and Bristol Myers Squibb.
Regeneron and CytomX expand cancer therapy deal to $4B
Regeneron and CytomX are combining masking and bispecific antibody technology to develop conditionally activated cancer treatments. Here's what the expanded partnership means for oncology pipelines.
Cellares to automate TScan's TCR therapy manufacturing ahead of 2026 trial
Cellares will test its Cell Shuttle and Cell Q systems to automate production of TSC-101, a gene-modified T cell therapy for blood cancer, before the drug enters pivotal trials in Q2 2026.
Eli Lilly bets $1.9B on Ascidian's gene-editing tech for kidney disease
Eli Lilly signed a $1.9 billion partnership with Ascidian Therapeutics to develop RNA exon editing treatments for monogenic kidney diseases. The deal marks Lilly's third major genetic medicine commitment this week.
Daraxonrasib Doubles Pancreatic Cancer Survival in Phase 3 Trial
Revolution Medicine's once-daily RAS inhibitor cut death risk by 60% in 500 patients with aggressive pancreatic cancer. Three other therapies showed clinical wins at ASCO 2026 in lung, blood, and prostate cancers.
Korea's biotech labs lure global pharma away from centralized support
Ecolab opened its first Asian bioprocessing lab in Korea this spring, part of a broader industry shift toward regional expertise. Korea now generates 2.2% of global continuous bioprocessing revenue.
McMaster lab finds first antibiotic that avoids all known bacterial resistance
Manikomycin targets a ribosomal site no antibiotic has exploited before, meaning bacteria have evolved no defenses against it. The compound works on multidrug-resistant bacteria and is the fourth new candidate from the lab in 14 months.